Guerbet SA – LSE:0ELV.L

Guerbet SA stock price today

EUR 37.55
+10.46
+38.66%
Financial Health
0
1
2
3
4
5
6
7
8
9

Guerbet SA stock price monthly change

-30.92%
month

Guerbet SA stock price quarterly change

-30.92%
quarter

Guerbet SA stock price yearly change

+38.59%
year

Guerbet SA key metrics

Market Cap
 315.22M
Enterprise value
 706.26M
P/E
 10.42
EV/Sales
 0.84
EV/EBITDA
 6.41
Price/Sales
 0.40
Price/Book
 0.87
PEG ratio
 0.16
EPS
 -1.36
Revenue
 1.53B
EBITDA
 189.66M
Income
 -17.24M
Revenue Q/Q
 N/A
Revenue Y/Y
 N/A
Profit margin
 3.9%
Oper. margin
 6.97%
Gross margin
 74.82%
EBIT margin
 6.97%
EBITDA margin
 12.32%

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Guerbet SA stock price history

Guerbet SA stock forecast

Guerbet SA financial statements

Profit Margin

Guerbet SA (LSE:0ELV.L): Profit margin
Jun 2022 371.07M 3.33M 0.9%
Dec 2022 382.20M -44.44M -11.63%
Jun 2023 378.63M 2.08M 0.55%
Dec 2023 407.05M 21.78M 5.35%
0ELV.L income statement history

Guerbet SA Financials Estimate

Guerbet SA (LSE:0ELV.L): Analyst Estimates
2025 925.65M 38.84M 4.2%
2026 986.86M 47.62M 4.83%

  • Analysts Price target

  • Financials & Ratios estimates

Show more
1.84%
Yield TTM
Guerbet SA (LSE:0ELV.L): Payout ratio
Payout ratio 19.26%
Guerbet SA (LSE:0ELV.L): Dividend Yield
2019 2.03%
2020 2.11%
2021 1.87%
2022 5.04%
2023 2.57%
0ELV.L dividends history

Debt to Assets

Guerbet SA (LSE:0ELV.L): Debt to assets
Sep 2022 939643000 560.07M 59.6%
Dec 2022 939643000 560.07M 59.6%
Jun 2023 991226000 620.96M 62.65%
Dec 2023 1025242000 646.97M 63.1%
0ELV.L balance sheet history

Cash Flow

Guerbet SA (LSE:0ELV.L): Cash Flow
Jun 2022 -8.03M -19.01M -29.21M
Dec 2022 33.92M -36.38M -14.78M
Jun 2023 -36.57M -25.85M 60.33M
Dec 2023 53.38M -34.07M -4.96M
0ELV.L cash flow history

Guerbet SA alternative data

Guerbet SA
Employees

Guerbet SA (LSE:0ELV.L): Employee count
Aug 2023 2,839
Sep 2023 2,839
Oct 2023 2,839
Nov 2023 2,839
Dec 2023 2,839
Jan 2024 2,839
Feb 2024 2,839
Mar 2024 2,839
Apr 2024 2,839
May 2024 2,920
Jun 2024 2,920
Jul 2024 2,920

Guerbet SA other data

Guerbet SA
Executives

Insider Compensation
Mr. Pierre André (1969) Chief Pharmaceutical Officer & Deputy Chief Executive Officer
 $11,500
Mr. François Nicolas Chief Digital Officer and Vice President of Contrast Injection Systems R&D
Ms. Petra Zalabak Vice President of HR, Health, Safety & Environment
Mr. David Hale Chief Executive Officer
Ms. Valérie Brissart Senior Vice President of Diagnostic Imaging
Ms. Anne-Laure Delasalle Vice President of Communications & Image and Director of Communications
Mr. Mathieu Elie Chief Commercial Officer of Asia Pacific
Mr. Jerome Estampes Chief Financial Officer
Mr. Pierre Desché Vice President of Devel., Medical & Regulatory Affairs
Ms. Gitte Hesselholt Chief Commercial Officer of Americas & EMEA

Frequently Asked Questions (FAQ)

  • What's the price of Guerbet SA stock today?

    One share of Guerbet SA stock can currently be purchased for approximately $37.55.

  • When is Guerbet SA's next earnings date?

    Unfortunately, Guerbet SA's (0ELV.L) next earnings date is currently unknown.

  • Does Guerbet SA pay dividends?

    Yes, Guerbet SA pays dividends and its trailing 12-month yield is 1.85% with 19% payout ratio. The last Guerbet SA stock dividend of $0.7 was paid on 2 Jul 2020.

  • How much money does Guerbet SA make?

    Guerbet SA has a market capitalization of 315.22M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 5.63% to 795.65M US dollars.

  • What is Guerbet SA's stock symbol?

    Guerbet SA is traded on the LSE under the ticker symbol "0ELV.L".

  • What is Guerbet SA's primary industry?

    Company operates in the Healthcare sector and Medical - Equipment & Services industry.

  • How do i buy shares of Guerbet SA?

    Shares of Guerbet SA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Guerbet SA's key executives?

    Guerbet SA's management team includes the following people:

    • Mr. Pierre AndrĂ© Chief Pharmaceutical Officer & Deputy Chief Executive Officer(age: 56, pay: $11,500)
    • Mr. François Nicolas Chief Digital Officer and Vice President of Contrast Injection Systems R&D
    • Ms. Petra Zalabak Vice President of HR, Health, Safety & Environment
    • Mr. David Hale Chief Executive Officer
    • Ms. ValĂ©rie Brissart Senior Vice President of Diagnostic Imaging
    • Ms. Anne-Laure Delasalle Vice President of Communications & Image and Director of Communications
    • Mr. Mathieu Elie Chief Commercial Officer of Asia Pacific
    • Mr. Jerome Estampes Chief Financial Officer
    • Mr. Pierre DeschĂ© Vice President of Devel., Medical & Regulatory Affairs
    • Ms. Gitte Hesselholt Chief Commercial Officer of Americas & EMEA

  • How many employees does Guerbet SA have?

    As Jul 2024, Guerbet SA employs 2,920 workers, which is 3% more then previous quarter.

  • When Guerbet SA went public?

    Guerbet SA is publicly traded company for more then 17 years since IPO on 4 Aug 2008.

  • What is Guerbet SA's official website?

    The official website for Guerbet SA is guerbet.com.

  • How can i contact Guerbet SA?

    Guerbet SA can be reached via phone at +33 1 45 91 50 00.

Guerbet SA company profile:

Guerbet SA

guerbet.com
Exchange:

LSE

Full time employees:

2,920

Industry:

Medical - Equipment & Services

Sector:

Healthcare

Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services. In addition, the company provides products for interventional radiology, including Lipiodol ethyl esters of iodinated fatty acids of poppyseed oil; Vectorio, a mixing and injection system for conventional trans-arterial chemoembolization; Patent Blue V, a blue dye; Axessio, a peripheral micro guidewire; and SeQure and DraKon, which are microcatheters. Further, it offers Hydra Vision, a digital imaging system for urological, gastroenterological, and gynecological treatment, as well as planning and diagnostic procedures; and urology accessories and consumables. The company was founded in 1926 and is headquartered in Villepinte, France.

+33 1 45 91 50 00
15, rue des Vanesses
Villepinte, 93420

:
ISIN: FR0000032526
: